Page 24 - Read Online

Page 16 of 16 de Santis et al. Hepatoma Res 2019;5:1 I http://dx.doi.org/10.20517/2394-5079.2018.65

41. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
42. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, et al. Which response criteria best help predict survival of patients with hepatocellular
carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012;262:708-18.
43. Lencioni R, Montal R, Torres F, Park JW, Decaens T, et al. Objective response by mRECIST as a predictor and potential surrogate
end-point of overall survival in advanced HCC. J Hepatol 2017;66:1166-72.
44. Edeline J, Palmer D, Blanc JF, Campillo-Gimenez B, Merle P, et al. mRECIST for systemic therapies: more evidence is required
before recommendations can be made. J Hepatol 2017;67:195.
45. Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, et al. MRECIST to predict survival in advanced hepatocellular carcinoma:
analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Liver Int 2017;37:1047-55.
46. Moga TV, Popescu A, Sporea I, Danila M, David C, et al. Is contrast enhanced ultrasonography a useful tool in a beginner’s hand?
How much can a computer assisted diagnosis prototype help in characterizing the malignancy of focal liver lesions? Med Ultrason
2017;19:252-8.
47. Kim Y, Furlan A, Borhani AA, Bae KT. Computer-aided diagnosis program for classifying the risk of hepatocellular carcinoma on MR
images following liver imaging reporting and data system (LI-RADS). J Magn Reson Imaging 2018;47:710-22.